Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis
Scholars in psychedelic bioethics have called for the inclusion of a variety of potential risks and benefits in ICDs. It will be important to continue debating which elements are worth including in ICDs such that potential research participants are presented with the most salient factors relevant to their decision about joining a study. We provide a table of best practices applied by our sample of ICDs.
Authors
- David B. Yaden (ORCID: https://orcid.org/0000-0002-9604-6227)
- Marianna Graziosi (ORCID: https://orcid.org/0000-0002-4177-3304)
- Kyle Patch
- Caleigh Propes (ORCID: https://orcid.org/0009-0002-3198-480X)
- Katherine Cheung (ORCID: https://orcid.org/0009-0003-3529-4109)
Institutions
- Hofstra University (US)
- Johns Hopkins University (US)
- Johns Hopkins Berman Institute of Bioethics (US)
- Behavioral Pharma (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- AJOB Empirical Bioethics
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1080/23294515.2025.2526339
- Citations
- 1
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.31